Analyzing AbbVie Stock: Challenges, Positive Indicators, and Investment Implications
Monday, 20 May 2024, 14:58
AbbVie Stock Analysis
A Wall Street analyst sees strong potential in AbbVie stock, projecting a price target of $200 from the current $165 level.
Reasoning Behind the Optimism
- Rising Revenue: AbbVie's revenue growth defies expectations post Humira's patent expiration.
- New Product Sales: Sales of Rinvoq and Skyrizi counterbalance the decline in Humira sales.
Strategic Acquisitions
- Cerevel Therapeutics Acquisition: The potential acquisition offers a new blockbuster drug in AbbVie's pipeline.
Investing in AbbVie at the current valuation and dividend yield may present lucrative opportunities for investors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.